USS Investment Management Ltd Raises Position in IQVIA Holdings Inc. $IQV

USS Investment Management Ltd lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.1% in the 4th quarter, HoldingsChannel reports. The firm owned 32,897 shares of the medical research company’s stock after buying an additional 4,807 shares during the quarter. USS Investment Management Ltd’s holdings in IQVIA were worth $7,418,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners increased its stake in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after purchasing an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after purchasing an additional 41,643 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.9%

IQVIA stock opened at $178.07 on Tuesday. The firm has a 50 day simple moving average of $173.65 and a 200 day simple moving average of $193.06. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04. The firm has a market capitalization of $29.72 billion, a price-to-earnings ratio of 22.07, a P/E/G ratio of 1.56 and a beta of 1.21.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the firm earned $2.70 EPS. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its board has initiated a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research note on Friday, March 6th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday. HSBC set a $210.00 price objective on shares of IQVIA in a research note on Wednesday, June 3rd. Finally, Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.